NuVasive, Inc. (NUVA)
(Delayed Data from NSDQ)
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$62.96 USD
+0.74 (1.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $62.96 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Analysts Estimate NuVasive (NUVA) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
NuVasive (NUVA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NuVasive (NUVA) Posts Q1 Preliminary Results, Withdraws View
by Zacks Equity Research
A decline in elective surgical procedures due to coronavirus outbreak weighs on NuVasive's (NUVA) preliminary revenue results for first-quarter 2020.
Here's Why You Should Hold on to NuVasive (NUVA) Stocks Now
by Zacks Equity Research
Investors continue to be optimistic about NuVasive (NUVA) on its strong segmental and international results in the fourth quarter of 2019.
Allscripts' Veradigm Business Line Unveils New Solution
by Zacks Equity Research
Allscripts' (MDRX) Veradigm business line introduces new solution that will drive growing medication adherence and improve patient care.
NuVasive (NUVA) Earnings and Revenues Beat Estimates in Q4
by Zacks Equity Research
NuVasive's (NUVA) Biologics business returns to growth in the fourth quarter of 2019.
What's in Store for IDEXX Laboratories' (IDXX) Q4 Earnings?
by Zacks Equity Research
IDEXX's (IDXX) is likely to report strong earnings for Q4, courtesy of a global surge in CAG Diagnostic revenues.
What's in Store for Align Technology's (ALGN) Q4 Earnings?
by Zacks Equity Research
Align Technology (ALGN) is expected to have gained from continued adoption of Invisalign system in Q4.
Can NuVasive (NUVA) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
NuVasive (NUVA) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?
by Zacks Equity Research
Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.
NuVasive (NUVA) Stock Dips Despite Strong Preliminary Q4 Show
by Zacks Equity Research
NuVasive's (NUVA) revenue growth will likely beat expectations for both the fourth quarter and 2019.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can Focus on High-Growth Area Up OrganiGram (OGI) Q1 Earnings?
by Zacks Equity Research
OrganiGram (OGI) is expected to have benefited from its firm focus on building brand equity and ongoing product innovation in the fiscal first quarter.
Can New Strategic Efforts Aid Apharia's (APHA) Q2 Earnings?
by Zacks Equity Research
Apharia (APHA) is successfully running its global cannabis business with more than 1,200 team members globally.
Can Cannabis Therapy Drive Aphria's (APHA) Q2 Earnings?
by Zacks Equity Research
Aphria (APHA) expects to deliver strong second-quarter fiscal 2020 results banking on solid performance of its cannabis therapy business.
Bio-Rad Gains on New Product Portfolio Despite Currency Woes
by Zacks Equity Research
Bio-Rad's (BIO) new product uptake in the United States is appreciative with the recent 510(k) clearance of the IH-Reader 24.
Here's Why You Should Add NuVasive Stock to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about NuVasive (NUVA) on its stellar segmental performance in Q3.
Syneos Health (SYNH) Hits a 52-Week High: What's Driving It?
by Zacks Equity Research
Syneos Health (SYNH) gains from several positive developments.
Edwards (EW) Rides on Innovation Despite Regulatory Issues
by Zacks Equity Research
Edwards Lifesciences' (EW) HemoSphere all-in-one monitoring platform is gaining momentum on the back of a strong rollout that sees a full-market launch.
NUVA vs. RMD: Which Stock Is the Better Value Option?
by Zacks Equity Research
NUVA vs. RMD: Which Stock Is the Better Value Option?
Here's Why You Should Hold on to Thermo Fisher Stock for Now
by Zacks Equity Research
Investors continue to be optimistic about Thermo Fisher (TMO) on its stellar segmental performance.
Here's Why You Should Hold on to Hill-Rom (HRC) Stock Now
by Zacks Equity Research
Investors can retain Hill-Rom (HRC) in their portfolio, courtesy of solid prospects.
Strong Pipeline Aids Tandem Diabetes Despite Stiff Rivalry
by Zacks Equity Research
Tandem Diabetes' (TNDM) products under development comprise AID systems, a next-generation hardware platform and connected (mobile) health offerings.
Nevro (NVRO) Hits New 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Nevro (NVRO) gains from several positive developments.
Zimmer Biomet Hits New 52-Week High: What's Driving It?
by Zacks Equity Research
Zimmer Biomet (ZBH) is optimistic about maintaining growth momentum on several recent positive developments.
6 MedTech Stocks That are Set to Beat the Market in 2020
by Trina Mukherjee
Banking on the three key trends, we zero in on six MedTech stocks that are likely to deliver stellar performance in 2020.